<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>PENDING</status><version>v2</version><patient-age>63</patient-age><report-id>SE-SANOFI-AVENTIS-2013SA003881</report-id><gender>male</gender><reactions><reaction>hypocalcaemia</reaction><reaction>paresthesia</reaction><reaction>muscle cramps</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>JEVTANA</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>ZOMETA</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>OMEPRAZOLE</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>FORLAX</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>MORPHINE</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>IBUPROFEN</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>DOLCONTIN</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>ALVEDON FORTE</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>CANODERM</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>SODIUM PICOSULFATE</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>10060862</indication></indications><patient-age>63</patient-age><outcomes><outcome>Required Inpatient Hospitalization</outcome></outcomes><country>Sweden</country><geo/></meta><original><ichicsr lang="en" xmlns="">
<ichicsrmessageheader>
<messagetype>ichicsr</messagetype>
<messageformatversion>2.1</messageformatversion>
<messageformatrelease>1.0</messageformatrelease>
<messagenumb>78948</messagenumb>
<messagesenderidentifier>SAAVPROD</messagesenderidentifier>
<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
<messagedateformat>204</messagedateformat>
<messagedate>20130125151123</messagedate>
</ichicsrmessageheader>
<safetyreport>
<safetyreportversion>1</safetyreportversion>
<safetyreportid>SE-SANOFI-AVENTIS-2013SA003881</safetyreportid>
<primarysourcecountry>SE</primarysourcecountry>
<occurcountry>SE</occurcountry>
<transmissiondateformat>102</transmissiondateformat>
<transmissiondate>2013-01-25</transmissiondate>
<reporttype>1</reporttype>
<serious code="1">Yes</serious>
<seriousnessdeath>2</seriousnessdeath>
<seriousnesslifethreatening>2</seriousnesslifethreatening>
<seriousnesshospitalization>1</seriousnesshospitalization>
<seriousnessdisabling>2</seriousnessdisabling>
<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
<receivedateformat>102</receivedateformat>
<receivedate>2013-01-16</receivedate>
<receiptdateformat>102</receiptdateformat>
<receiptdate>2013-01-16</receiptdate>
<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
<companynumb>SE-SANOFI-AVENTIS-2013SA003881</companynumb>
<duplicate>1</duplicate>
<reportduplicate>
<duplicatesource>SWE-MPA</duplicatesource>
<duplicatenumb>1244547</duplicatenumb>
</reportduplicate>
<primarysource>
<reportergivename>PRIVACY</reportergivename>
<reportermiddlename>PRIVACY</reportermiddlename>
<reporterfamilyname>PRIVACY</reporterfamilyname>
<reporterorganization>Medical Product Agency</reporterorganization>
<reporterstreet>PRIVACY</reporterstreet>
<reportercity>PRIVACY</reportercity>
<reportercountry>SE</reportercountry>
<qualification code="3">Other Health Professional</qualification>
</primarysource>
<primarysource>
<reportergivename>PRIVACY</reportergivename>
<reportermiddlename>PRIVACY</reportermiddlename>
<reporterfamilyname>PRIVACY</reporterfamilyname>
<reporterstreet>PRIVACY</reporterstreet>
<reportercity>PRIVACY</reportercity>
<reportercountry>SE</reportercountry>
<qualification code="2">Pharmacist</qualification>
</primarysource>
<sender>
<sendertype>1</sendertype>
<senderorganization>sanofi-aventis</senderorganization>
<senderdepartment>US Affiliate Pharmacovigilance</senderdepartment>
<sendergivename>Barbara</sendergivename>
<senderfamilyname>Rullo</senderfamilyname>
<senderstreetaddress>55A-435 55 Corporate Drive</senderstreetaddress>
<sendercity>Bridgewater</sendercity>
<senderstate>NJ</senderstate>
<senderpostcode>08807</senderpostcode>
<sendercountrycode>US</sendercountrycode>
<sendertel>9089816698</sendertel>
<sendertelcountrycode>1</sendertelcountrycode>
<senderfax>9089877894</senderfax>
<senderfaxcountrycode>1</senderfaxcountrycode>
<senderemailaddress>Barbara.Rullo@sanofi-aventis.com</senderemailaddress>
</sender>
<receiver>
<receivertype>2</receivertype>
<receiverorganization>ZZFDA</receiverorganization>
<receiverdepartment>Center for Drug Evaluation and Research</receiverdepartment>
<receiverstreetaddress>5600 Fishers lane</receiverstreetaddress>
<receivercity>Rockville</receivercity>
<receiverstate>MD</receiverstate>
<receiverpostcode>20857</receiverpostcode>
<receivercountrycode>US</receivercountrycode>
<receivertel>3018273237</receivertel>
<receivertelcountrycode>1</receivertelcountrycode>
<receiveremailaddress>aersesub@cder.fda.gov</receiveremailaddress>
</receiver>
<patient>
<patientinitial>PRIVACY</patientinitial>
<patientonsetage>63</patientonsetage>
<patientonsetageunit>801</patientonsetageunit>
<patientagegroup>5</patientagegroup>
<patientsex code="1">Male</patientsex>
<reaction>
<primarysourcereaction>hypocalcaemia</primarysourcereaction>
<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
<reactionmeddrallt>10020947</reactionmeddrallt>
<termhighlighted>4</termhighlighted>
<reactionstartdateformat>102</reactionstartdateformat>
<reactionstartdate>20121029</reactionstartdate>
<reactionfirsttime>73</reactionfirsttime>
<reactionfirsttimeunit>804</reactionfirsttimeunit>
<reactionlasttime>1</reactionlasttime>
<reactionlasttimeunit>803</reactionlasttimeunit>
<reactionoutcome code="2">recovering/resolved</reactionoutcome>
</reaction>
<reaction>
<primarysourcereaction>paresthesia</primarysourcereaction>
<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
<reactionmeddrallt>10033987</reactionmeddrallt>
<termhighlighted>4</termhighlighted>
<reactionstartdateformat>102</reactionstartdateformat>
<reactionstartdate>20121029</reactionstartdate>
<reactionfirsttime>73</reactionfirsttime>
<reactionfirsttimeunit>804</reactionfirsttimeunit>
<reactionlasttime>1</reactionlasttime>
<reactionlasttimeunit>803</reactionlasttimeunit>
<reactionoutcome code="2">recovering/resolved</reactionoutcome>
</reaction>
<reaction>
<primarysourcereaction>muscle cramps</primarysourcereaction>
<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
<reactionmeddrallt>10028295</reactionmeddrallt>
<termhighlighted>4</termhighlighted>
<reactionstartdateformat>102</reactionstartdateformat>
<reactionstartdate>20121029</reactionstartdate>
<reactionfirsttime>73</reactionfirsttime>
<reactionfirsttimeunit>804</reactionfirsttimeunit>
<reactionlasttime>1</reactionlasttime>
<reactionlasttimeunit>803</reactionlasttimeunit>
<reactionoutcome code="2">recovering/resolved</reactionoutcome>
</reaction>
<test>
<testdateformat>102</testdateformat>
<testdate>20121029</testdate>
<testname>10006948</testname>
<testresult>S-CA 0.97</testresult>
<testunit>MMOL/L</testunit>
<lowtestrange>2.15</lowtestrange>
<hightestrange>2.50</hightestrange>
<moreinformation>2</moreinformation>
</test>
<drug>
<drugcharacterization code="1">suspsect</drugcharacterization>
<medicinalproduct>JEVTANA</medicinalproduct>
<drugbatchnumb>UNKNOWN</drugbatchnumb>
<drugauthorizationnumb>NDA 201023</drugauthorizationnumb>
<drugadministrationroute code="065">Unknown</drugadministrationroute>
<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
<drugindication>10060862</drugindication>
<drugstartdateformat>102</drugstartdateformat>
<drugstartdate>2012-08-17</drugstartdate>
<drugstartperiod>73</drugstartperiod>
<drugstartperiodunit>804</drugstartperiodunit>
<druglastperiod>1</druglastperiod>
<druglastperiodunit>803</druglastperiodunit>
<drugenddateformat>102</drugenddateformat>
<drugenddate>2012-10-22</drugenddate>
<drugtreatmentduration>67</drugtreatmentduration>
<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
<actiondrug code="1">Drug Withdrawn</actiondrug>
<drugadditional code="Form:Unknown"/>
<activesubstance>
<activesubstancename>CABAZITAXEL</activesubstancename>
</activesubstance>
</drug>
<drug>
<drugcharacterization code="2">concomitant</drugcharacterization>
<medicinalproduct>ZOMETA</medicinalproduct>
<activesubstance>
<activesubstancename>ZOLEDRONIC ACID</activesubstancename>
</activesubstance>
</drug>
<drug>
<drugcharacterization code="2">concomitant</drugcharacterization>
<medicinalproduct>OMEPRAZOLE</medicinalproduct>
<activesubstance>
<activesubstancename>OMEPRAZOLE</activesubstancename>
</activesubstance>
</drug>
<drug>
<drugcharacterization code="2">concomitant</drugcharacterization>
<medicinalproduct>FORLAX</medicinalproduct>
<activesubstance>
<activesubstancename>MACROGOL</activesubstancename>
</activesubstance>
</drug>
<drug>
<drugcharacterization code="2">concomitant</drugcharacterization>
<medicinalproduct>MORPHINE</medicinalproduct>
<activesubstance>
<activesubstancename>MORPHINE</activesubstancename>
</activesubstance>
</drug>
<drug>
<drugcharacterization code="2">concomitant</drugcharacterization>
<medicinalproduct>IBUPROFEN</medicinalproduct>
<drugdosageform normalized="film-coated tablet">FILM-COATED TABLET</drugdosageform>
<activesubstance>
<activesubstancename>IBUPROFEN</activesubstancename>
</activesubstance>
</drug>
<drug>
<drugcharacterization code="2">concomitant</drugcharacterization>
<medicinalproduct>DOLCONTIN</medicinalproduct>
<drugdosageform normalized="prolonged-release tablet">PROLONGED-RELEASE TABLET</drugdosageform>
<activesubstance>
<activesubstancename>MORPHINE SULFATE</activesubstancename>
</activesubstance>
</drug>
<drug>
<drugcharacterization code="2">concomitant</drugcharacterization>
<medicinalproduct>ALVEDON FORTE</medicinalproduct>
<activesubstance>
<activesubstancename>PARACETAMOL</activesubstancename>
</activesubstance>
</drug>
<drug>
<drugcharacterization code="2">concomitant</drugcharacterization>
<medicinalproduct>CANODERM</medicinalproduct>
<activesubstance>
<activesubstancename>UREA</activesubstancename>
</activesubstance>
</drug>
<drug>
<drugcharacterization code="2">concomitant</drugcharacterization>
<medicinalproduct>SODIUM PICOSULFATE</medicinalproduct>
<drugdosagetext>strength: 7.5 mg/ml</drugdosagetext>
<drugdosageform normalized="oral drops, solution">ORAL DROPS, SOLUTION</drugdosageform>
<activesubstance>
<activesubstancename>SODIUM PICOSULFATE</activesubstancename>
</activesubstance>
</drug>
<summary>
<narrativeincludeclinical>This serious unsolicited case from Sweden (Local reference number: SE2013023) was received on 16-Jan 2013 from <Semaphore x="2597467" class="Race" value="Swedish" score="1.00" ID="C43861">Swedish </Semaphore>Health Authority (ref: 124457) via a <Semaphore x="2394141" class="Occupation" value="Pharmacist" score="1.00" ID="C51840">pharmacist </Semaphore>and <Semaphore x="1805433" class="Procedure" value="Concern About Finances" score="1.00" ID="C104604">concerns </Semaphore>a <Semaphore x="1387834" class="Patient Age" value="63" score="1.00" ID=""><Semaphore x="5960701642276865" class="Patient Age" value="63" score="1.00" ID="">63 </Semaphore>year old </Semaphore>male patient who experienced <Semaphore x="3020845" class="MedDRA LLT" value="Hypocalcaemia" score="1.00" ID="10020947">hypocalcaemia</Semaphore>, <Semaphore x="2377148" class="Disease or Finding" value="Paresthesia" score="1.00" ID="C28177">paresthesia </Semaphore>and <Semaphore x="2246100" class="Disease or Finding" value="Muscle Cramp" score="1.00" ID="C34827">muscle cramps </Semaphore>whilst receiving <Semaphore x="263074" class="Medicine" value="cabazitaxel" score="0.97" ID="300901">cabazitaxel </Semaphore>(<Semaphore x="753911" class="Medicine" value="Jevtana" score="0.49" ID="300903">Jevtana</Semaphore>) for <Semaphore x="2429227" class="Disease or Finding" value="Prostate Carcinoma by AJCC v6 Stage" score="1.00" ID="C90521">prostate cancer</Semaphore>.On 17-Aug 2012, the patient commenced <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">therapy </Semaphore>with <Semaphore x="263074" class="Medicine" value="cabazitaxel" score="0.97" ID="300901">cabazitaxel </Semaphore>(dosage <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">regimen</Semaphore>, batch/lot number and expiration date: unspecified). It was reported that 4 <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">regimens </Semaphore>had been given and the last together with <Semaphore x="1384774" class="Medicine" value="zoledronic acid" score="0.74" ID="274011">zoledronic <Semaphore x="2147465" class="Procedure" value="Lysergide Measurement" score="1.00" ID="C75354">acid</Semaphore></Semaphore>. Last dose of <Semaphore x="263074" class="Medicine" value="cabazitaxel" score="0.97" ID="300901">cabazitaxel </Semaphore>was received on 22-Oct 2012. It was reported that 1 week after the fourth <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>on 29-Oct 2012, the patient was admitted to hospital for <Semaphore x="2102792" class="Disease or Finding" value="Leg Cramp" score="1.00" ID="C34762">cramps in legs</Semaphore>, ongoing for 14 days. It was reported that the <Semaphore x="2246100" class="Disease or Finding" value="Muscle Cramp" score="1.00" ID="C34827">cramps </Semaphore>came 슿after <Semaphore x="2524194" class="Procedure" value="Sitting Inactive in Public Place" score="1.00" ID="C106686">sitting </Semaphore>for a long time together with small pricking슿 (<Semaphore x="2377148" class="Disease or Finding" value="Paresthesia" score="1.00" ID="C28177">paresthesia</Semaphore>). On the same day <Semaphore x="3020845" class="MedDRA LLT" value="Hypocalcaemia" score="1.00" ID="10020947">hypocalcaemia </Semaphore>was noted (S <Semaphore x="1670132" class="Procedure" value="Calcium Measurement" score="1.00" ID="C64488">Ca </Semaphore>0.97, reference 2.15-2.50 mmol/L). No information was provided concerning corrective <Semaphore x="1568617" class="Disease or Finding" value="Behavior-Related Disorder" score="1.00" ID="C35470">conduct</Semaphore>.The <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">therapy </Semaphore>with <Semaphore x="263074" class="Medicine" value="cabazitaxel" score="0.97" ID="300901">cabazitaxel </Semaphore>was discontinued. <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">Outcome </Semaphore>for the events of <Semaphore x="3020845" class="MedDRA LLT" value="Hypocalcaemia" score="1.00" ID="10020947">hypocalcaemia</Semaphore>, <Semaphore x="2377148" class="Disease or Finding" value="Paresthesia" score="1.00" ID="C28177">paresthesia </Semaphore>and <Semaphore x="2246100" class="Disease or Finding" value="Muscle Cramp" score="1.00" ID="C34827">muscle cramps </Semaphore>was reported as recovering.The patient was taking <Semaphore x="1384774" class="Medicine" value="zoledronic acid" score="0.74" ID="274011">zoledronic <Semaphore x="2147465" class="Procedure" value="Lysergide Measurement" score="1.00" ID="C75354">acid </Semaphore></Semaphore>(<Semaphore x="1385161" class="Medicine" value="Zometa" score="0.49" ID="242959">Zometa</Semaphore>), <Semaphore x="949575" class="Medicine" value="Omeprazole" score="0.49" ID="273990">omeprazole</Semaphore>, macrogol (Forlax), <Semaphore x="885260" class="Medicine" value="Morphine" score="0.49" ID="280811">morphine </Semaphore>(nos), <Semaphore x="696671" class="Medicine" value="Ibuprofen" score="0.49" ID="271165">ibuprofen </Semaphore>(Brufen), <Semaphore x="885083" class="Medicine" value="Morphine Sulfate" score="0.49" ID="243166">morphine sulfate </Semaphore>(Dolcontin), <Semaphore x="2737985" class="MedDRA LLT" value="Analgesic drug level" score="1.00" ID="10060090">paracetamol </Semaphore>(Alvedon Forte), <Semaphore x="1316129" class="Medicine" value="Urea" score="0.49" ID="194669">urea </Semaphore>(Canoderm) and <Semaphore x="2536895" class="Procedure" value="Sodium Measurement" score="1.00" ID="C64809">sodium </Semaphore>picosulfate (Cilaxoral) concomitantly. No other relevant medical history, concurrent condition and past medications were reported.The relationship between the events; <Semaphore x="3020845" class="MedDRA LLT" value="Hypocalcaemia" score="1.00" ID="10020947">hypocalcaemia</Semaphore>, <Semaphore x="2377148" class="Disease or Finding" value="Paresthesia" score="1.00" ID="C28177">paresthesia </Semaphore>and <Semaphore x="2246100" class="Disease or Finding" value="Muscle Cramp" score="1.00" ID="C34827">muscle cramps </Semaphore>and <Semaphore x="263074" class="Medicine" value="cabazitaxel" score="0.97" ID="300901">cabazitaxel </Semaphore>was reported as possible.No further information was available from <Semaphore x="2597467" class="Race" value="Swedish" score="1.00" ID="C43861">Swedish </Semaphore>Heath Authority.</narrativeincludeclinical>
<sendercomment>Sanofi-Aventis company comment dated 18 Jan 13: Although the role of cabazitaxel cannot be denied for the events of hypocalcemia and paraesthesia however its role cannot be judged in isolation as other drug are also given concomitantly, the role of which cannot be underestimated.</sendercomment>
</summary>
</patient>
</safetyreport>
</ichicsr></original></faers>